Rotigotine
Class: Nonergot-derivative Dopamine Receptor Agonists
- Antiparkinsonian Agents
VA Class: CN500
Chemical Name: 5,6,7,8-Tetrahydro-6-[propyl [2-(2-thienyl)ethyl]amino-(6S)-1-naphthalenol
Molecular Formula: C19H25NOS
CAS Number: 99755-59-6
Brands: Neupro
Introduction
Nonergot-derivative dopamine receptor agonist.
Uses for Rotigotine
Parkinsonian Syndrome
Symptomatic management of idiopathic parkinsonian syndrome.
Efficacy demonstrated in patients with early parkinsonian syndrome not receiving concomitant levodopa therapy and in patients with advanced parkinsonian syndrome receiving concomitant levodopa therapy.
Restless Legs Syndrome
Symptomatic management of moderate-to-severe primary restless legs syndrome (RLS; also called Willis-Ekbom disease).
Nonergot-derivative dopamine receptor agonists (e.g., pramipexole, ropinirole, rotigotine) generally considered among the drugs of first choice for treating restless legs syndrome.
Rotigotine Dosage and Administration
Administration
Transdermal Administration
Administer percutaneously by topical application of a transdermal system (Neupro). Apply transdermal system (or “patch”) once daily at a convenient time (day or night) and at approximately the same time each day. May apply without regard to meals.
Instruct patients in the proper use and disposal of the transdermal system and advise patients to read the patient information, including the instructions for use, before beginning therapy and each time drug is refilled.
Apply transdermal system immediately after removal from its pouch and removal of the protective liner.
Apply to clean, dry, intact healthy skin on the front of the abdomen, thigh, hip, flank, shoulder, or upper arm by firmly pressing the system with the palm of the hand for 30 seconds with the adhesive side touching the skin to ensure good contact, particularly around the edges.
Avoid application sites that are oily, irritated, or damaged; also avoid sites where the patch may be rubbed by tight clothing, under a waistband, and skin folds.
If application to a hairy area is necessary, shave hair at the application site at least 3 days prior to application; do not use creams, lotions, oils, ointments, or powders on skin where patch will be placed.
Move application site on a daily basis (i.e., from the right side to the left side, from the upper body to the lower body). Do not apply transdermal system to the same application site more than once every 14 days. (See Application Site Reactions under Cautions.)
Wear each transdermal system continuously for 24 hours. If a system becomes dislodged during period of use or if a patient forgets to change the system, apply a new system for the remainder of the day; on the following day, change the patch according to regular time schedule. May tape edges of the transdermal system in place with bandage tape if patient experiences difficulty with patch adhesion.
After handling a transdermal system,..
